Navigation Links
Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
Date:4/25/2011

m) for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has two projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to announce the first quarter 2011 results; and the potential for XIAFLEX to be used in multiple indications.  

Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.

A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2010, which is on file with
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2010 Financial Results, Guidance for 2011
2. Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011
3. CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011
4. Zacharon Pharmaceuticals Announces Research and Development Collaboration With Pfizer to Develop Drugs for Multiple Rare Disorders
5. Meda to License Elidel to Valeant Pharmaceuticals
6. Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
7. Lexicon Pharmaceuticals to Present at the 10th Annual Needham Healthcare Conference
8. Reportlinker Adds Upstream Processing in Biopharmaceuticals - Increasing Use of Low-Cost Disposable Bioreactors to Drive the Upstream Bioprocessing Market
9. Onyx Pharmaceuticals Announces Plans to Amend Phase 3 FOCUS Study for European Registration
10. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
11. VentiRx Pharmaceuticals Presents Positive Clinical and Pre-Clinical Data at American Academy of Allergy Asthma & Immunology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Shimadzu Scientific Instruments has released the DSES-1000 long-travel ... for measuring displacement in rubber and other soft ... distance, the DSES-1000 can measure elongations up to ... mm. In addition, it achieves +/- 0.2 percent ... +/- 100 µm below 50-mm stroke. , The ...
(Date:9/30/2014)... Md. , Sept. 30, 2014  RegeneRx ... today announced that it has received a Canadian ... by Actin-Sequestering Peptides.  This patent includes claims using ... numerous other actin-sequestering peptides for these purposes.  The ... About RegeneRx Biopharmaceuticals, Inc. ( www.regenerx.com ) ...
(Date:9/30/2014)... 30, 2014  KemPharm, Inc., a clinical-stage specialty ... of proprietary new molecular entity (NME) prodrugs, announced ... Office (USPTO) issued U.S. Patent No. 8,816,083 to ... Benzoic Acid Derivatives and Heteroaryl Carboxylic Acid Conjugates ... Thereof." The patent, which extends through ...
(Date:9/30/2014)... 30, 2014 The custom stainless steel ... Product Show 2014. The Boston Area Chapter of ISPE ... annual, day-long event for Wed., Oct. 1 at Gillette ... be the largest in ISPE Boston’s long history, with ... 3,000 attendees expected. , HOLLOWAY AMERICA President David ...
Breaking Biology Technology:Shimadzu’s New Long-Travel Extensometer Increases Precision for Soft Material Testing 2RegeneRx Receives Canadian Patent for Inhibition or Reversal of Skin Aging 2KemPharm, Inc. Receives Patent from the USPTO for Novel Prodrug of Hydromorphone, KP511 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 2HOLLOWAY AMERICA to Exhibit at ISPE Boston Product Show 2014 3
... The " Acute Myeloid Leukemia Therapeutics ... analyzes and studies the major market drivers, restraints, ... and Japan. Browse market data ... Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - ...
... ALTO, Calif., Dec. 19, 2011 Varian Medical Systems (NYSE: ... results for the first quarter of fiscal year 2012 following ... The news release will be followed by a teleconference available ... release and a link to the conference call webcast will ...
... electrons move past atoms in a solid, their charge distorts ... wave in the lattice affects the electrons motion, in analogy ... riding it. This interaction results in a thermoelectric effect that ... be known as phonon-drag, because it can be quantified from ...
Cached Biology Technology:MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020 2MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020 3Varian Medical Systems Schedules First Quarter FY2012 News Release and Conference Call 2A 50-year quest to isolate the thermoelectric effect is now over: Magnon drag unveiled 2
(Date:9/30/2014)... think of nature as something that we enjoy when we ... Or do we think of ourselves as a part of ... what about a house? , The answers to these ... our actions, our speech and in cultural artifacts. , A ... Washington, the American Indian Center of Chicago and the Menominee ...
(Date:9/30/2014)... 30, 2014--Sea monkeys have captured the popular attention of ... observable life cycle -- sold as dehydrated eggs, these ... little more than a tank of salt water. ... Like other zooplankton, brine shrimp vertically migrate in large ... to the surface at night and retreating deeper during ...
(Date:9/30/2014)... and engineers, led by Clemson University associate professor ... grant from the U.S. Department of Energy,s Experimental ... direct positive impact on South Carolina in the ... contaminants. , "Understanding the scientific and engineering needs ... of nuclear technologies is imperative if South Carolina ...
Breaking Biology News(10 mins):The cultural side of science communication 2Laser-guided sea monkeys show how zooplankton migrations may affect global ocean currents 2Researchers get $5.25 million to advance nuclear technologies in South Carolina 2
... of 3-D printing a major body organ like a kidney ... national hub for human organs partly due to regenerative medicine ... seem to be coming faster than the public can understand ... legal and moral considerations. To spark the national ...
... in the African rainforests has halved the number of primates. ... in the number of primates causes a reduction in the ... a reduction in the numbers of important fruit trees and ... research from Lund University in Sweden. The destruction of ...
... extraction from soybean seeds. It is rich in protein, which ... the seeds and dependent on the line, and can also ... The study looked at the role soybeans could have ... lines which were high in oleic acid and protein, the ...
Cached Biology News:'After the Genome' tackles tough questions about medicine, miracles and morality 2'After the Genome' tackles tough questions about medicine, miracles and morality 3Hunting for meat impacts on rainforest 2
Application: for RNase- decontamination , Registered Trademark of Ambion. ,Special grade: for molecular biology Density: 1.00 g/mL (20 C) Suitab tst: RNase decontamination in accordance...
... Application: A cleaning agent for ... surfaces, countertops, and pipettors. ... eliminating RNase contamination from microcentrifuge ... reactions. ,RNase Zap (R) ...
Mol wt: average mol wt12,360.96 Da by calculation...
... is part of a series of media originally ... Weiss et al. for the large scale propagation ... medium is primarily used for the growth and ... the propagation of viruses in these cell lines. ...
Biology Products: